Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

Core Viewpoint - Santhera Pharmaceuticals has appointed Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026, succeeding Geert Jan van Daal, who will retire after 11 years with the company [1][5]. Group 1: Leadership Transition - Marc Clausse brings over 25 years of international experience in the life sciences industry, with expertise in specialty, oncology, and rare diseases [2]. - Geert Jan van Daal joined Santhera in 2015 and played a significant role in the European launch of AGAMREE® (vamorolone), enhancing patient access [5][6]. Group 2: Marc Clausse's Background - Clausse previously served as VP of International Strategy & Operations at Mirum Pharmaceuticals, where he successfully executed the company's international strategy and built regional commercial infrastructure [3]. - At GSK, he led the ovarian cancer portfolio to a market-leading position and integrated Tesaro UK following its acquisition [4]. Group 3: Company Overview - Santhera Pharmaceuticals focuses on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [7]. - The company has an exclusive license for AGAMREE® (vamorolone), which is approved in multiple regions including the U.S., EU, UK, and Canada for the treatment of Duchenne muscular dystrophy (DMD) [7][8].